VEGFA and age-related macular degeneration: The VEGF Trap-EYE Investigation of Efficacy and Safety in Wet AMD (VIEW) studies investigating the efficacy of aflibercept in four treatment group (0.5 mg per 4 weeks, 2 mg per 8 weeks, 2 mg per 8 weeks after 3 loading doses, and 0.5 mg ranibizumab per 4 weeks) shows that mean change in BCVA between the groups were equal, meaning that 2 mg of aflibercept bimonthly is non-inferior compared to ranibizumab.